Combination of olaparib, durvalumab and fulvestrant in patients with advanced ER+/HER2- breast cancer and selected genomic alterations: results of the DOLAF trial.

Date publication

septembre 2025

Journal

Clinical cancer research : an official journal of the American Association for Cancer Research

Auteurs

Membres identifiés du Cancéropôle Est :
Pr CURTIT Elsa

Tous les auteurs :
Guiu S, Balmaña J, Lemercier P, Follana P, Gonçalves A, Bigot F, Frenel JS, Brain E, Mailliez A, Chakiba Brugere C, Curtit E, Derbel O, Dalenc F, Derquin F, Duhoux F, Canon JL, Pimentel I, Chevalier LM, Buisson A, Guyonneau C, Lemonnier J, Delaloge S, Bachelot T

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40986529

Résumé

Previous data suggest synergy between PARP inhibition and immune checkpoint blockade in different genetic settings. The estrogen receptor (ER) pathway remains a key target in metastatic breast cancer whatever the genomic context. This study assess the activity of the combination of PARP, ER, and PDL1 inhibition among patients with metastatic breast cancer and relevant genomic alterations.

Référence

Clin Cancer Res. 2025 09 23;: